Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse events · hormone‐sensitive prostate cancer

Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).

1 finding from 1 review

Degarelix for treating advanced hormone‐sensitive prostate cancer 2021 · Cochrane Headline outcomes only
RR 0.8 [0.62, 1.05]
9 studies · 2750 participants
Low